Numbers

The Numbers — Centene Corporation

Centene is a $195B-revenue, low-margin managed-care insurer trading at $41.82 — roughly 60% below its 2018-2021 peaks — after a $6.7B FY2025 GAAP loss driven by Marketplace utilization spikes and a goodwill impairment. The balance sheet is intact ($17.9B in cash and investments, no near-term refinancing wall, debt-to-equity 0.88), and management is guiding adjusted FY2026 EPS above $3.00 versus an FY2025 adjusted print of $2.08. The single metric most likely to rerate or derate the stock is the Marketplace medical loss ratio (MLR) trajectory — sustained improvement validates the "transitory cost shock" thesis, while another quarter of utilization surprise would prove the 2025 collapse was structural.

Quality Check — Is It Built To Survive?

Centene's quality profile is mixed. Cash flow generation has held up (operating cash flow of $5.1B in 2025 even through the loss year), the debt load is moderate for a payer, and current ratio expanded sharply as Marketplace receivables built. But returns on equity collapsed and operating margin went negative — the business is not currently earning its cost of capital.

Twenty Years Of Revenue, Twenty Years Of Thin Margins

Revenue has compounded at roughly 26% annually since 2006, an 85x expansion driven by Medicaid expansion, ACA Marketplace launch, the Health Net acquisition (2016) and the WellCare deal (2020). What that tells you is more important than the size: this is a flow-through business. Premium dollars in, claims dollars out, with 1–3% net margin across the cycle in good years.

The 2025 break is the worst since 2006. The previous five-year average operating margin (2020-2024) was 1.89%; the 20-year average is 1.78%. The chart's message: this business has never been "expensive" by margin standards. The current question is whether 2025 represents a step-change or a one-year shock around Marketplace pricing.

What Q3 2025 Did To The Story

3Q25 is the entire FY2025 problem. Premium revenue kept expanding (+18% YoY each of the last four quarters), but a $6.6B impairment-and-elevated-claims charge in Q3 drove a single-quarter loss larger than the previous twenty quarters of profit combined. Q4 partly normalized (still a $1.1B loss), and Q1 2026 consensus is $2.13 EPS — a rapid V-shape if achieved.

Cash Generation — Are The Earnings Real?

Operating cash flow has consistently exceeded reported GAAP net income across the cycle, the opposite signature of a low-quality earnings stream. The 2024 anomaly — $154M operating cash flow versus $3.3B net income — was driven by an enormous receivables build (Medicaid redetermination timing). FY2025 reversed that: $5.1B of operating cash flow despite the $6.7B loss, because the goodwill writedown was non-cash and the working capital cycle normalized.

Trailing-five-year FCF/NI conversion (2021-2025) is roughly 2.0x including the 2025 loss year — a positive signal that GAAP profits understate the underlying cash economics, and that 2025's earnings reset is heavily non-cash. Capex is structurally tiny: less than 0.5% of revenue, even after the WellCare integration. This is an asset-light premium-collection business; the binding constraint is regulatory capital, not capex.

Capital Allocation — Defensive Posture

Centene has never paid a meaningful dividend. The capital story is M&A (WellCare 2020), debt management, and opportunistic buybacks. Buybacks have collapsed — Q1 2025 repurchases were $41M, down 73% YoY — as management conserved cash heading into the Marketplace stress. The credit facility was doubled to $4B in early 2025 (zero drawn) as a defensive backstop.

Balance Sheet — Levered, But Not Stressed

Net debt swung from +$4.6B in 2024 to -$0.3B in 2025 — Centene is now in a net-cash position because cash and investments rose to $17.9B while long-term debt actually declined to $17.4B. Debt/equity ticked up to 0.88, but only because equity contracted via the $6.7B loss, not because debt grew. Long-dated maturities are spread (5.000% notes due 2034, 5.375% notes due 2054) and the new $4B revolver is undrawn — there is no near-term refinancing pressure even at the current credit spread.

Valuation — Below Twenty-Year Mean By Every Cut

Centene's trailing P/E is undefined for FY2025. Using year-end price and reported EPS for years with positive earnings shows the stock has de-rated dramatically: from ~40x earnings during the 2017-2018 growth era to under 10x in 2024 and effectively stranded in 2025.

EV/EBITDA at 3.8x is roughly one-third of the Healthcare Plans industry median (10.5x). The discount is real and reflects three things the market is pricing in: (1) doubt that 2026 adjusted EPS will print above $3.00 as guided, (2) Marketplace MLR uncertainty, and (3) the industry-wide overhang from the Change Healthcare cyber incident and Medicare Advantage rate cuts that have hit every payer.

Twenty Years Of Stock Price — Where Are We In The Range?

The stock has round-tripped: $41.82 today is comparable to the 2011-2012 level, despite revenue having grown roughly 37x since. 52-week range: $25.21 – $63.86. Five-year peak: $97.22 (mid-2022).

Peers — Centene Is The Cheapest On Sales, The Bleakest On Margin

The decision-relevant gap is EV/Sales: 0.09x for Centene versus 0.83x for UnitedHealth and 0.48x for Elevance — a 5-9x discount on the multiple the market actually uses to value low-margin payers. Two reasons that gap exists: Centene has the lowest exposure to commercial employer-group business (its book is overwhelmingly Medicaid + Marketplace, the most rate-sensitive segments) and it produced the only deeply negative net margin in the cohort. The cohort itself is going through a tough year — Humana's ROE of 7% and Molina's of 4.5% confirm this is a sector-wide margin reset, not a Centene-specific blowup, but Centene is the most exposed.

The Estimate Reset — Where Consensus Sits Now

The 90-day trend is constructive: FY2025 estimates revised up by ~6% (Centene actually beat their cratered baseline), FY2026 estimates ticked up to $3.02. FY2027 has drifted down by ~1.5% — the market is more confident in the snapback for 2026 than in the durable normalization for 2027. That gap matters: a stable $4 EPS by 2027 at a 14x multiple gets you to $56; a $3.50 print earns 11x and you stay near $40.

Fair Value Range — Bear, Base, Bull

At $41.82 the market is already pricing close to the bear-base midpoint — i.e., it does not yet believe management's "above $3.00" 2026 guide will be met cleanly. The reward-to-risk skews positive if FY26 prints near consensus: ~9% downside to the bear, ~55% upside to the bull, with the base scenario implying ~7% upside that aligns with the median sell-side target.

Bottom Line

The numbers confirm that Centene is a structurally low-margin, asset-light premium aggregator with strong cash conversion across the cycle and a balance sheet that is more resilient than the loss-year headlines suggest — net cash position, undrawn $4B revolver, manageable maturity wall. The numbers contradict the "broken business" narrative implied by the price chart: revenue is still compounding, gross margin actually expanded in 2025, and the FY2025 loss was dominated by a non-cash goodwill writedown, not a collapse in operating cash flow. What to watch in 1H 2026: the medical loss ratio in Marketplace (a sustained 50-100 bps improvement validates the snapback thesis), management's success rate in repricing 2026 rates upward, and the cadence of consensus FY2027 EPS revisions — that line, more than anything else, will tell you whether 2025 was a reset or a regime change.